Novo Nordisk debuts Wegovy weight-loss pill in US
Digest more
Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable 2x
The Canadian Press on MSN
Novo Nordisk Canada considers competing with generics through renamed lower-price Ozempic
Health Canada is currently considering nine submissions from other drug companies to make generic semaglutide.
FDA oral Wegovy, solid fundamentals, and low P/E vs. Eli Lilly. Click for this updated look at NVO stock prospects as compared to LLY.
Chooses industry leading Vault CRM to empower commercial teams with next-generation CRM capabilities and agentic AI
Danish obesity drugmaker Novo Nordisk's head of public affairs in the U.S. has left the company, according to an internal memo seen by Reuters, at a time when the firm is battling to revive its fortunes in its top market.
The patent in question is due to lapse in March next year. The court is scheduled to take up Natco's challenge for further hearing in February
"As such, it is a modest positive, suggesting Nvidia remains on track, broadly in line with or slightly ahead of expectations, rather than a moment that fundamentally changes the investment case." Shares in Danish pharmaceuticals firm Novo Nordisk (NOVO-B.
Americans seeking to lose weight now have a new option – taking Wegovy as a daily pill, rather than a weekly injection.
Feedback